The U.S. FDA granted Juno Therapeutics Inc. and partner Celgene Corp.'s investigational drug JCAR017 a breakthrough therapy designation for the treatment of patients with relapsed/refractory aggressive large B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and certain other lymphomas.

The European Medicines Agency's Committee for Medicinal Products for Human Use and Committee for Advanced Therapies granted JCAR017 access to the priority medicines scheme for relapsed/refractory diffuse large B-cell lymphoma. A study is expected to begin in 2017.

The drug is currently not approved in any country.